Esperion (ESPR) Receives a Buy from Needham

Needham analyst Chad Messer assigned a Buy rating to Esperion (ESPRResearch Report) today and set a price target of $114.00. The company’s shares closed last Tuesday at $14.20.

According to TipRanks.com, Messer is a 4-star analyst with an average return of 6.6% and a 41.7% success rate. Messer covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Phasebio Pharmaceuticals, and Aeglea Biotherapeutics.

Currently, the analyst consensus on Esperion is a Moderate Buy with an average price target of $56.86.

See today’s analyst top recommended stocks >>

Based on Esperion’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $7.98 million and GAAP net loss of $90.94 million. In comparison, last year the company earned revenue of $1.84 million and had a GAAP net loss of $78.25 million.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ESPR in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.